Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart

By Zhong Wang, T. Zhu, Chunping Qiao, Liqiao Zhou, Bing Wang, Jian Zhang, Chun-lian Chen, Juan Li, Xiao Xiao. Nature Biotechnology, 2005

626 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors (2010, positive): “Of note, we observed a lower prevalence of total IgG to AAV8 (38%), which has been shown to be a robust vector for achieving high levels of transgene expression in liver, muscle, and heart (Gao et al. , 2002, 2004; Nakai et al. , 2005; Z. Wang et al. , 2005; Toromanoff et al. , 2008).”
Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches. (2016, background): “For instance, the AAV subtypes 6, 8, and 9 are cardiotropic when given systemically (175, 215, 285).”
Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. (2006, background): “applications of systemic intravenous administration of rAAV8 vectors are being exploited to treat animal models of various human diseases that were previously thought to be difficult to treat by gene therapy [12,13].”
Adeno-associated virus serotypes: vector toolkit for human gene therapy. (2006, background): “In liver, AAV8 has been shown to be a robust vector for achieving high levels of transgene expression [16] [17].”